FAST NEWS: Junshi Biosciences Revenue Doubles, Loss Narrows in 2021
The latest: Shanghai Junshi Biosciences Co. Ltd. (1877.HK) announced its 2021 preliminary annual results on Friday evening, reporting its loss narrowed 55.7% last year to 739 million yuan ($116 million),…
RELATED ARTICLES
-
Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?
1877.HK 688180.SHG
-
Junshi hopes new scientist CEO can cure its woes
1877.HK 688180.SHG
-
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
-
Missing the Covid boat, Junshi stumbles back to old business
1877.HK 688180.SHG
-
FAST NEWS: Junshi Biosciences announces A-Share buyback
1877.HK 688180.SHG
- CHINA BULLETIN: Economic Distress Signals Keep Coming
-
FAST NEWS: Zai Lab’s loss narrows on growing revenue
ZLAB.US 9688.HK
Discover hidden China stock gems in our weekly newsletter